Leadership
Converting scientific discoveries into significant advanced treatments in patient care
MEET OUR TEAM
JUSTINAS MACIULAITIS, MD, PhD
Founder, Chief Executive Officer, Member of Board
Ph.D. in translational regenerative medicine
Dr. Maciulaitis provides visionary leadership and strategic direction to the company. With his medical and research background, he possesses a deep understanding of the healthcare industry and the development of therapeutic products. Developed a tissue-engineered advanced therapeutic medicinal product for cartilage regeneration
RUTA INSODAITE, PhD
Chief Manufacturing Officer
Ph.D. in genetic biotechnology and cell therapies
Dr. Insodaite ensures that R&D is compliant and prepares for regulatory submissions. Her scientific expertise and extensive experience in biomedical research contribute to the advancement of the company's therapeutic products pipeline
NERINGA KAMINSKIENE, MPharm
Chief Quality Officer
Extensive pharmaceutical Quality Control experience at the manufacturing hospital pharmacy of the largest public hospital in Central Eastern Europe
Mrs. Kaminskiene ensures the foundation for excellence by establishing quality standards throughout product development. She designs and implements proactive protocols and procedures that anticipate and prevent potential quality issues. Her attention to detail and regulatory knowledge are crucial in maintaining product safety and efficacy
RUTA AUGLIENE, MD, PhD
Chief Medical Officer
More than 10 years of experience in clinical nephrology, kidney transplantation, and hemodialysis. Member of the Lithuanian Nephrology, Dialysis, and Transplantation Association and the European Renal Association
Dr. Rūta guides the clinical team, ensures rigorous therapy evaluations, and fosters collaborations with medical professionals to drive innovation in renal health solutions. Her commitment to excellence and patient care is essential to KELI Therapeutics' mission to develop effective therapies for unmet medical needs in renal disease
MICHAEL MENDICINO, PhD
Chief Regulatory Officer
International, multidisciplinary professional consultant with over 24 years translational research, clinical development, regulatory affairs, and clinical strategy, commercialization and branding experience
Dr. Mendicino's commitment to advancing innovative therapies while adhering to regulatory standards supports KELI Therapeutics' mission to bring transformative treatments to market efficiently and responsibly
EDMUNDAS SALNA
Chief Financial Officer
Experience across sales planning, marketing control, financial management, and negotiations with key regional pharmaceutical customers, suppliers, and distributors. Former head of sales for Roche Baltic states arm, and Merck
Mr. Salna is responsible for overseeing the company’s financial operations, including budgeting, forecasting, and financial reporting
MEET KELI'S BOARD OF DIRECTORS
TROELS JORDANSEN
Executive Chairman
Biotech Corporate Executive with more than 30-year track record in co-founding start-ups and scaling commercial/corporate teams and organizations. Executed 200M EUR in fundraising and has closed deal transactions of over $500 million
Mr. Troels' strategic vision and leadership will guide KELI Therapeutics in achieving its objectives and advancing innovative healthcare solutions
S. SOHAIL AHMED, MD, MBA
Board Director
Sohail received his medical degree from the University of Texas Health Science Center-Houston with certification in Internal Medicine and Clinical Immunology/Rheumatology. His research fellowship training includes cancer immunology at MD Anderson Cancer Center and cardiovascular sciences at the National Institutes of Health. He had clinical faculty appointments at UT-Houston, Boston University Medical Center, and Harvard/Massachusetts General Hospital, and his industry experience includes Novartis, GSK, Roche, and start-up companies like Galapagos and Kling Biotherapeutics. Sohail has designed and conducted many pioneering clinical trials with KOLs in Europe and the USA across a wide range of indications.
JUSTINAS MACIULAITIS, MD, PhD
Founder, Chief Executive Officer, Member of Board
Ph.D. in translational regenerative medicine
Dr. Maciulaitis provides visionary leadership and strategic direction to the company. With his medical and research background, he possesses a deep understanding of the healthcare industry and the development of therapeutic products. Developed a tissue-engineered advanced therapeutic medicinal product for cartilage regeneration
MEET KELI'S ADVISORY BOARD
ALGIRDAS LUKOSEVICIUS, PharmD
Global business executive expert at international finance, government, medical groups, consumer, IT, legal and manufacturing, pharmaceuticals, biotech, medical device, non-profit, venture capital, private equity. Managed >200 M USD.
Prof. JANIS ANCANS
Former expert at European Medicines Agency at non-clinical evaluation. Connects with healthcare regulatory bodies, ensuring KELI's products meet EU EMA and US FDA standards
Prof. RENALDAS URNIEZIUS
Two patents assignee. Upstream and downstream bioprocess experties. Leads pilot and large-scale production, working with cell processing specialists to ensure GMP compliance
MARCO EIJKEN, PhD
An associate professor at Aarhus University Hospital. Specializes in renal medicine. His work involves pre-clinical studies in mesenchymal stromal cell therapy and the production of clinical-grade mesenchymal stromal cells